FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386912840> ?p ?o ?g. }

• W4386912840 endingPage "4667" @default.
• W4386912840 startingPage "4667" @default.
• W4386912840 abstract "Renal function impairment (RI) is a common complication in multiple myeloma (MM). However, limited data exist on the safety and efficacy of anti-MM regimens in patients with severe RI, as these patients are frequently excluded from clinical trials. This investigator-initiated multicentric phase II GMMG-DANTE trial evaluated daratumumab, bortezomib, and dexamethasone (DVd) in relapsed or refractory (r/r) MM patients with severe RI. r/rMM patients with ≥1 prior treatment line and a GFR <30 mL/min/1.73 m2 or undergoing hemodialysis were eligible and received eight cycles of DVd followed by daratumumab maintenance. The trial closed prematurely after 22/36 planned patients. The primary endpoint was overall response rate (ORR). Median age of patients was 70 (range 55-89) years, with a median GFR of 20.1 mL/min/1.73 m2 (interquartile range, 9.4-27.3 mL/min/1.73 m2), and eight patients under hemodialysis. Median number of prior lines was two (range 1-10). The trial was successful, albeit with premature termination, as it met its primary endpoint, with an ORR of 67% (14/21). The rates of partial response, very good partial response, and complete response were 29%, 29%, and 10%, respectively (n = 6, 6, and 2). Fourteen patients (67%) achieved renal response. After median follow-up of 28 months, median progression-free survival was 10.4 months; median overall survival was not reached. Higher-grade toxicity was mainly hematologic, and non-hematologic toxicities ≥Grade 3 were mostly infections (24%). The prospective GMMG-DANTE trial investigating DVd exclusively in r/rMM patients with severe RI showed efficacy and safety to be comparable to data from patients without RI." @default.
• W4386912840 created "2023-09-22" @default.
• W4386912840 creator A5006343827 @default.
• W4386912840 creator A5015972472 @default.
• W4386912840 creator A5019620720 @default.
• W4386912840 creator A5022522496 @default.
• W4386912840 creator A5033573338 @default.
• W4386912840 creator A5046661856 @default.
• W4386912840 creator A5048007851 @default.
• W4386912840 creator A5048727363 @default.
• W4386912840 creator A5055684106 @default.
• W4386912840 creator A5055916434 @default.
• W4386912840 creator A5067657650 @default.
• W4386912840 creator A5068697219 @default.
• W4386912840 creator A5070221339 @default.
• W4386912840 creator A5078383767 @default.
• W4386912840 creator A5088691462 @default.
• W4386912840 date "2023-09-21" @default.
• W4386912840 modified "2023-10-17" @default.
• W4386912840 title "Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial" @default.
• W4386912840 cites W2001151538 @default.
• W4386912840 cites W2005548627 @default.
• W4386912840 cites W2009858783 @default.
• W4386912840 cites W2038304921 @default.
• W4386912840 cites W2041547777 @default.
• W4386912840 cites W2143720184 @default.
• W4386912840 cites W2144728882 @default.
• W4386912840 cites W2146105386 @default.
• W4386912840 cites W2299833483 @default.
• W4386912840 cites W2402003835 @default.
• W4386912840 cites W2512106959 @default.
• W4386912840 cites W2785647909 @default.
• W4386912840 cites W2890977830 @default.
• W4386912840 cites W2947874495 @default.
• W4386912840 cites W2948728876 @default.
• W4386912840 cites W2988984460 @default.
• W4386912840 cites W3027520213 @default.
• W4386912840 cites W3043410628 @default.
• W4386912840 cites W3118681630 @default.
• W4386912840 cites W3205534443 @default.
• W4386912840 cites W3207809849 @default.
• W4386912840 cites W4310207270 @default.
• W4386912840 cites W4381469475 @default.
• W4386912840 cites W4382930345 @default.
• W4386912840 doi "https://doi.org/10.3390/cancers15184667" @default.
• W4386912840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37760637" @default.
• W4386912840 hasPublicationYear "2023" @default.
• W4386912840 type Work @default.
• W4386912840 citedByCount "0" @default.
• W4386912840 crossrefType "journal-article" @default.
• W4386912840 hasAuthorship W4386912840A5006343827 @default.
• W4386912840 hasAuthorship W4386912840A5015972472 @default.
• W4386912840 hasAuthorship W4386912840A5019620720 @default.
• W4386912840 hasAuthorship W4386912840A5022522496 @default.
• W4386912840 hasAuthorship W4386912840A5033573338 @default.
• W4386912840 hasAuthorship W4386912840A5046661856 @default.
• W4386912840 hasAuthorship W4386912840A5048007851 @default.
• W4386912840 hasAuthorship W4386912840A5048727363 @default.
• W4386912840 hasAuthorship W4386912840A5055684106 @default.
• W4386912840 hasAuthorship W4386912840A5055916434 @default.
• W4386912840 hasAuthorship W4386912840A5067657650 @default.
• W4386912840 hasAuthorship W4386912840A5068697219 @default.
• W4386912840 hasAuthorship W4386912840A5070221339 @default.
• W4386912840 hasAuthorship W4386912840A5078383767 @default.
• W4386912840 hasAuthorship W4386912840A5088691462 @default.
• W4386912840 hasBestOaLocation W43869128401 @default.
• W4386912840 hasConcept C119060515 @default.
• W4386912840 hasConcept C121332964 @default.
• W4386912840 hasConcept C126322002 @default.
• W4386912840 hasConcept C126894567 @default.
• W4386912840 hasConcept C141071460 @default.
• W4386912840 hasConcept C141341695 @default.
• W4386912840 hasConcept C142424586 @default.
• W4386912840 hasConcept C203092338 @default.
• W4386912840 hasConcept C2776364478 @default.
• W4386912840 hasConcept C2777478702 @default.
• W4386912840 hasConcept C2778063415 @default.
• W4386912840 hasConcept C2780401358 @default.
• W4386912840 hasConcept C2781119759 @default.
• W4386912840 hasConcept C31760486 @default.
• W4386912840 hasConcept C535046627 @default.
• W4386912840 hasConcept C71924100 @default.
• W4386912840 hasConcept C87355193 @default.
• W4386912840 hasConcept C90924648 @default.
• W4386912840 hasConceptScore W4386912840C119060515 @default.
• W4386912840 hasConceptScore W4386912840C121332964 @default.
• W4386912840 hasConceptScore W4386912840C126322002 @default.
• W4386912840 hasConceptScore W4386912840C126894567 @default.
• W4386912840 hasConceptScore W4386912840C141071460 @default.
• W4386912840 hasConceptScore W4386912840C141341695 @default.
• W4386912840 hasConceptScore W4386912840C142424586 @default.
• W4386912840 hasConceptScore W4386912840C203092338 @default.
• W4386912840 hasConceptScore W4386912840C2776364478 @default.
• W4386912840 hasConceptScore W4386912840C2777478702 @default.
• W4386912840 hasConceptScore W4386912840C2778063415 @default.
• W4386912840 hasConceptScore W4386912840C2780401358 @default.
• W4386912840 hasConceptScore W4386912840C2781119759 @default.
• W4386912840 hasConceptScore W4386912840C31760486 @default.

• next